A-Cold

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of A-Cold

Property Description
Active Ingredient Bromhexine hydrochloride
Pharmacological Class Mucolytic agent (Secretolytic)
Common Use Managing thick, excessive mucus
Origin Synthetic compound
Forms Tablet, Syrup, Oral solution

What Type of Medicine is A-Cold? (Classification and Origin)

A-Cold is a pharmaceutical preparation distinguished by its active ingredient, Bromhexine hydrochloride, and classified as a mucolytic and secretolytic agent. This places the medication in the class of expectorants, which aid in the clearance of respiratory secretions. The active substance itself is a synthetic compound, chemically derived from the plant alkaloid vasicine, ensuring a consistent and predictable therapeutic profile. Its classification as a mucolytic aligns with its targeted action on respiratory mucus.

Composition and Available Pharmaceutical Preparations

The A-Cold formulation is designed as a single-ingredient product (monodrug), relying solely on Bromhexine hydrochloride for its therapeutic effect alongside necessary excipients. The manufacturer makes the drug available in multiple dosage forms, most commonly as a tablet, syrup, and oral solution. The syrup and oral solution preparations, often used for the pediatric patient group, utilize an aqueous base/vehicle, distinguishing them from the solid tablet form. This variety in preparations provides flexibility for the oral route of administration, making it suitable for situations requiring effective management of tenacious mucus.

What is the General Purpose of This Mucolytic Agent?

The general purpose of this mucolytic agent is to support the body’s function by chemically thinning out thick, heavy mucus and promoting its efficient clearance from the airways. The core action of Bromhexine is to break down the specific components within the mucus that cause its high viscosity, a mechanism known as fluidization of secretions. Bromhexine's secretolytic properties enable the management of tenacious respiratory secretions. This process helps relieve the sensation of blockage by ensuring the mucus is less heavy and sticky.

What side effects are possible with A-Cold?

Possible Side Effects and Safety Information

The safety profile for A-Cold, containing Bromhexine hydrochloride, is officially categorized based on regulatory frequency classifications and System-Organ Classes (SOCs). The most commonly reported issues are associated with Gastrointestinal disorders, classified as Uncommon (occurring in up to 1 in 100 individuals). These include nausea, vomiting, diarrhoea, and upper abdominal pain.

Official Adverse Reaction Classifications

Classification Examples of Reactions
Uncommon Nausea, Vomiting, Diarrhoea, Upper Abdominal Pain
Rare Hypersensitivity Reactions, Rash, Urticaria
Not Known Anaphylactic Shock, Severe Cutaneous Reactions (SCARs), Bronchospasm

Serious Safety Considerations

The most serious events documented in regulatory sources are classified with a frequency of Not Known (cannot be estimated from available data). These include severe allergic reactions such as Anaphylactic Shock and Severe Cutaneous Adverse Reactions (SCARs), specifically Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The occurrence of SCARs is noted to be in temporal association with administration.

Safety notes specify required caution in patients with severe hepatic or renal impairment due to potential reduction in drug clearance. Use is not recommended during pregnancy (especially the first trimester) and lactation. Furthermore, the official label restricts concomitant use with antitussives (cough suppressants) or secretion-drying medications due to opposing pharmacological effects.

Overdose and Emergency Response

Overdose Manifestations

The official regulatory documentation for A-Cold (Bromhexine hydrochloride) describes the necessary response to a potential overdose event. Clinical manifestations reported in accidental overdose cases are documented as being consistent with the known side effects observed at therapeutic doses. These presentations typically involve general symptoms such as headache, nausea, and vomiting.

When to Seek Immediate Medical Help

Regulatory agencies mandate that immediate medical attention must be sought following a suspected or confirmed overdose. This requirement is based on the possibility of severe or life-threatening outcomes. Symptoms that officially require urgent intervention include difficulty in breathing and signs consistent with angioedema, such as swelling of the face, lips, mouth, or throat. Authorities require patients to immediately contact a Poisons Information Centre or emergency services upon the recognition of these specific manifestations.

Official Overdose Management

Clinical management for A-Cold overdose is officially restricted to providing symptomatic and supportive treatment. This approach is necessary because the regulatory prescribing information does not document the existence of a specific antidote to reverse the effects of Bromhexine hydrochloride. Clinical assessment and observation by healthcare professionals are required to manage all resulting manifestations.

Therapeutic Uses of A-Cold

What A-Cold Treats: Main Uses and Benefits

The medication is considered relevant in therapeutic areas involving increased discomfort or tension related to respiratory secretions. It is commonly used to help with the management of mucus from the airways in patients with short- or long-term diseases of the lungs. It is applied across domains where additional symptomatic support may be appropriate.


Managing Viscous Secretions in Acute Episodes

A-Cold is commonly used for managing symptom clusters that may become intense or disruptive, leading to a productive cough with notably thick mucus. It is relevant in conditions involving recurrent or episodic manifestations, such as Chronic Bronchitis, COPD, and acute bronchitis, and is often applied in symptomatic management during the common cold or flu when heavy mucus is present.

The medication supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.

“It provides supportive relief when symptoms intensify and short-term symptomatic assistance is needed.”


Quick Fact: Relief for Viscous Mucus The medication is considered relevant for easing symptoms that are associated with thick, heavy phlegm, which can create noticeable physiological strain and interfere with daily comfort.

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Who Can and Cannot Use A-Cold? (Bromhexine Hydrochloride)

Official regulatory documentation defines eligibility for A-Cold based on absolute contraindications and population-specific restrictions. The medicine is contraindicated for individuals with a known hypersensitivity to bromhexine hydrochloride or any of the formulation's inactive ingredients. Use is also frequently contraindicated in children under 2 years of age due to the risk of respiratory obstruction from an inability to clear secretions effectively.


Eligibility Restrictions and Cautionary Use

Population Group Regulatory Status and Limitation
Age 2 to 6 Years Use is often not recommended or restricted to the advice of a healthcare professional.
Pregnancy (1st Trimester) Not recommended; use only if potential benefit outweighs risk, as documented in labeling.
Lactation/Breastfeeding Not recommended; the active substance may pass into breast milk.
Severe Organ Impairment Use with caution in patients with severe hepatic (liver) or renal (kidney) impairment due to reduced clearance of the substance.
Comorbidities Caution is necessary for patients with a history of gastric or duodenal ulcers.

Standard labeled use is established for adults and adolescents (typically 12 years and older) who do not possess any contraindications or requiring conditional use as listed above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for A-Cold (Bromhexine hydrochloride) is officially documented as having a low potential for clinically significant drug-drug interactions. Regulatory information, consistent across international authorities, notes no formal combinations are classified as contraindicated due to an interaction risk.

Documented Exposure Effects

The most specific interaction documented involves the co-administration of this medicine with certain antibiotics, including Amoxicillin and Erythromycin. This co-administration is formally noted to increase the concentration of the antibiotic agent specifically in the sputum and bronchopulmonary secretions.

General Interaction Status

The official labeling states that relevant interactions with major metabolic pathways, such as the Cytochrome P450 enzymes (e.g., CYP 2C9 and 3A4), are considered unlikely based on accumulated clinical data. Furthermore, no significant known interactions with alcohol are formally reported. Co-administration is permissible with or without food, and no mandatory timing separation rules are documented for co-administration with other substances.

Population Considerations

A specific consideration noted in official documents is that the clearance of the active substance or its metabolites may be reduced in patient populations with severe hepatic impairment or severe renal failure. This consideration pertains to the alteration of the drug’s overall exposure profile in these specific conditions.

Mechanism of Action

Chemical Depolymerization of Mucus Fibers

The mechanism of A-Cold (Bromhexine hydrochloride) affects the biophysical structure of respiratory secretions and modulates pulmonary fluid dynamics, influencing the clearance pathway. The primary mucolytic action involves acting on the acid mucopolysaccharide fibers within the mucus gel layer. By promoting the enzymatic breakdown of these long biopolymer chains, the mechanism causes a reduction in the dynamic viscosity and tenacity of the secretions, resulting in a more fluid state.


Secretagogue Activity and Surfactant Induction

The drug exhibits secretagogue properties by stimulating the serous glands to increase the aqueous (sol-layer) fluid content and simultaneously induces Pneumocytes Type II to secrete pulmonary surfactant. This dual action influences the aqueous layer required for ciliary function and decreases the surface tension of the secretions, which affects adhesion to the epithelium.


Modulation of Mucociliary Transport Dynamics

The collective molecular actions of depolymerization and fluid/surfactant induction converge to modulate the Mucociliary Clearance (MCC) Pathway. The resulting fluidity and reduced adhesion influence the cilia to beat effectively against the thinned secretions, influencing the mechanical transport and the physiological process of secretion removal from the airways.

Dosage and Administration Information

A-Cold (Bromhexine hydrochloride) is officially administered via the oral route using available forms such as tablets, syrups, or solutions. An intravenous (IV) or intramuscular (IM) route is also recognized for the injection solution in specific clinical settings. The official dosing principles are based on the standardized quantity, frequency, and duration of use as defined by established protocols.

The standard oral dosing for adults and adolescents (12+ years) is generally 8 mg to 16 mg per dose. This regimen is typically repeated up to three times per day (TID), with the total daily amount restricted to a maximum of 48 mg. The medication can be taken with or without food, although some labels recommend taking it immediately following meals.

For the pediatric population aged 2 to 11 years, the labeled dose is lower and age-specific, generally ranging from 2 mg to 8 mg per dose. A critical aspect of the use protocol is the short-term course duration, which generally does not exceed 8 to 14 days without re-evaluation by a health professional. Furthermore, procedural constraints exist for the injectable preparation: it must be administered slowly, and the solution must not be mixed with alkaline solutions to prevent chemical precipitation. Dose adjustments are also considered necessary for patients with severe hepatic or renal impairment due to potential reductions in drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for A-Cold


Research Evidence for Managing Thick Mucus in Chronic Respiratory Conditions

Research has been conducted on the use of A-Cold (Bromhexine hydrochloride) in patients with chronic respiratory issues, such as chronic bronchitis and certain stable phases of COPD, where symptoms include the production of thick, excessive mucus. These studies were primarily designed to explore the effect of the medication over intermediate time intervals, often lasting several weeks. The evidence base includes controlled clinical trials and observational settings that focused on adults with established, long-term conditions.

These studies were used in research exploring how the physical nature of the mucus changes. Findings describe patterns observed in the studies that were associated with a measured alteration in the characteristics of the sputum. The study data for these physical properties were described as consistent with changes in viscosity. However, when researchers monitored physiological strain or stress using functional measures, such as tests of lung capacity, the data showed patterns related to functional imbalance that were often mixed or not clearly distinguishable from control groups. This research contributes to understanding symptom patterns by detailing the observed changes in secretions but research does not determine whether an individual will respond similarly in terms of long-term functional improvement.

Research Evidence for Acute Respiratory Episodes

A significant portion of the evidence, particularly from older trials, was applied in studies examining short-term symptom patterns during acute respiratory infections, such as acute bronchitis, where symptoms involve a productive cough with notably heavy phlegm. These studies were conducted during periods of increased symptom activity in both adult and some historic pediatric populations.

In these acute research scenarios, studies explored outcomes related to physical discomfort, such as measurements of the time to symptom improvement for specific events like cough or pulmonary rales. Data show patterns related to measurements of a shorter time to symptom improvement or remission in some trials when compared to control groups. However, findings were mixed when comparing the overall study results of A-Cold against placebo for the entire acute episode. Evidence quality varies across studies, with a prevalence of older trials whose methodologies may affect the certainty of the overall results when combined in modern systematic reviews.


Areas of Uncertainty and Remaining Research Gaps

Research highlights what is known and what is still uncertain about A-Cold. A key limitation is the heterogeneity of the evidence, particularly when data is pooled into meta-analyses, which can lead to mixed findings regarding overall clinical success. Furthermore, many outcomes relied heavily on patient-reported subjective endpoints, such as perceived cough relief, making the quantification of objective measurement more challenging. Regulatory reviews have noted that data for certain groups, particularly young children, remain insufficient to establish a clear evidence pattern in this age bracket, and certainty remains low for many non-adult populations.

Frequently Asked Questions (FAQ)

Common questions about A-Cold (FAQ)

Q: Does A-Cold work on the cause of the cold, or just the symptoms?

A: A-Cold is categorized as a mucolytic adjuvant medicine, which means it helps clear mucus. Its official purpose is to manage symptoms like thick, excessive mucus associated with respiratory conditions, such as the common cold. The product information describes its effect as reducing mucus viscosity to provide symptomatic relief.


Q: What signs might indicate a rare but serious side effect from A-Cold?

A: Official product information notes that certain rare but serious side effects are possible. Signs that may indicate a serious adverse reaction include swelling of the face or throat, sudden difficulty in breathing (anaphylaxis), or the development of a severe skin rash or blistering (known as Severe Cutaneous Adverse Reactions or SCARs).


Q: What is the risk of combining A-Cold with other cough or cold medicines?

A: Official regulatory documents advise avoiding combination of A-Cold with cough suppressants (also called antitussives). This is described as a precautionary measure because cough suppressants can hinder the body's ability to clear the thinned mucus from the airways.


Q: Can individuals with asthma or COPD safely use A-Cold?

A: Regulatory documents note that caution is warranted for individuals with existing respiratory conditions like asthma. This caution is noted due to the reported, though rare, risk of bronchospasm (a sudden tightening of the airways). Research has examined its effects in patients with chronic conditions, including COPD.


Q: What is the difference between A-Cold and other common cold remedies on the market?

A: A-Cold is classified as a single-ingredient mucolytic agent, meaning its primary mechanism is to thin and loosen mucus to aid clearance. This is distinct from many common cold remedies which often combine several ingredients, such as fever reducers (e.g., acetaminophen), decongestants, or antihistamines.


Q: Do different formulations of A-Cold (liquid, tablet, capsule) work differently or faster?

A: Official pharmacokinetic studies examine how the drug is absorbed by the body. Data for the liquid and tablet formulations indicate that the Time to Peak Concentration is approximately 1 hour for both. This suggests that the absorption is rapid for both the solid and liquid oral dosage forms.


Q: Is A-Cold effective for a dry cough or a wet cough?

A: The medication is designed to manage conditions associated with thick, excessive mucus (viscid mucoid secretions). For this reason, official product indications typically do not list its use for a dry cough (one that produces no mucus).


Q: How quickly can a person expect to feel the effects of A-Cold?

A: Regulatory pharmacokinetic data, which describe how the drug moves through the body, indicate that the medicine is rapidly absorbed. The Time to Peak Plasma Concentration is generally noted to occur around 1 hour following an oral dose.


Q: How long does the effect of a single dose of A-Cold typically last?

A: The total duration that the active substance remains in the body is characterized by its terminal elimination half-life. Studies indicate that this half-life is highly variable among individuals, with official documentation noting a range of approximately 6.6 to 31.4 hours after a single dose.


Q: Is it safe to take A-Cold if I have a history of high blood pressure?

A: Official labeling advises that caution is warranted for individuals with certain pre-existing conditions. Regulatory documents may list existing high blood pressure as a condition where advice is recommended prior to use, depending on the specific product formulation.


Q: Is it normal to feel a little drowsy after taking A-Cold?

A: The official side effect profile lists central nervous system effects classified as uncommon or rare, such as dizziness and headache. However, drowsiness is generally not listed as one of the commonly or uncommonly reported adverse reactions in the regulatory documentation.


Q: Can A-Cold be taken at the same time as common pain relievers like acetaminophen or ibuprofen?

A: Regulatory interaction screening does not commonly report a specific unfavorable interaction with common pain relievers like acetaminophen or ibuprofen. However, a general precaution in the official documents advises caution for individuals with a history of gastric ulcers.


Q: Does A-Cold come in a non-drowsy formulation?

A: Regulatory side effect listings indicate that drowsiness is generally not listed as an undesirable effect, classifying the medicine as a non-sedating formulation. This distinguishes it from other drug classes where sedation is a common side effect.


Q: Is it safe to drive or operate machinery while using A-Cold?

A: Official product information notes that, absent side effects like dizziness, the product is not expected to impair the ability to drive or operate machinery when used as recommended. However, possible side effects like dizziness should be considered.


Q: Does A-Cold affect heart rate or blood pressure?

A: The active substance is generally not commonly associated with direct cardiovascular effects. However, regulatory documents note that caution is warranted for patients with pre-existing conditions, including high blood pressure or heart disease.


Q: Does A-Cold contain alcohol?

A: The presence of alcohol depends entirely on the specific product formulation. The syrup or oral solution forms may contain ethanol (alcohol) as an excipient, but some regulated products are specifically labeled as alcohol-free.


Q: Can A-Cold cause dry mouth?

A: Official regulatory documents list dry mouth as a possible side effect of the medicine. This symptom is typically grouped with other reactions affecting the digestive system.

How should A-Cold be stored and disposed of?

How to Store and Dispose of A-Cold (Bromhexine Hydrochloride)

The medicine must be stored and disposed of according to regulatory requirements to maintain stability and prevent accidental harm.

Storage Requirements

A-Cold must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from excessive heat. It is mandated to keep the product in its original container, ensure the container is tightly closed, and protect it from both light and moisture. Do not freeze the product. As with all medications, it must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired A-Cold should be done using a drug take-back program or mail-back collection envelope where available. If no program is accessible, the medicine may be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container for disposal in the household trash. Do not dispose of the product by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of A-Cold found in:

A-Z Index: